Meeting
2016 Genitourinary Cancers Symposium
Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy: A “real life” retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy.
Authors
Maria Agnese Fabbri
Division of Oncology, Ospedale Belcolle, Viterbo, Rome, Italy
Maria Agnese Fabbri , Paolo Marchetti , Enrico Cortesi , Daniele Santini , Teresa Gamucci , Francesco Angelini , Isabella Sperduti , Flavia Longo , Arianna Pellegrino , Annalisa Milano , Silvia Quadrini , ML Mancini , Francesca Primi , Fabrizio Nelli , Raffaele Ratta , Enzo Ruggeri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 337)
DOI
10.1200/jco.2016.34.2_suppl.337
Abstract #
337
Poster Bd #
D21
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).
First Author: Johann S. De Bono
Poster
2014 Genitourinary Cancers Symposium
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Antoine Angelergues
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2023 ASCO Annual Meeting
Concurrent chemo-hormonal therapy of enzalutamide (ENZ) and cabazitaxel (CAB) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final analysis of objective response rate (ORR), radiographic progression-free survival (rPFS), and overall survival (OS).
First Author: Alexandra Sokolova